Connect with us

Technology

EMERGE Reports First Quarter 2024 Results

Published

on

Q1 Gross Merchandise Sales1 (“GMS”) of $7.65M compared to $7.61M in Q1 2023Q1 Revenue of $5.0M compared to $5.3M in Q1 2023Q1 Gross Profit increased to $2.1M compared to $2.0M in Q1 2023Q1 Gross Margin improved to 43% compared to 38% in Q1 2023Q1 Adjusted EBITDA1 improved to $(99K) compared to $(526K) in Q1 2023Net Income from Continuing Operations improved to $9K compared to Net Loss of  $(2.4M) in Q1 2023

TORONTO, May 28, 2024 /CNW/ – EMERGE Commerce Ltd. (TSXV: ECOM) (“EMERGE” or the “Company”), a premium e-commerce brand portfolio, today announced results for its three months ended March 31, 2024. Copies of the interim financial statements and MD&A are available on the Company’s profile on SEDAR at www.sedar.com.

This marks EMERGE’s first financial report which classifies WholesalePet (“WSP”) as discontinued operations, with prior period results also restated to reflect the reclassification. EMERGE completed its sale of WSP in January 2024.

Ghassan Halazon, Founder and CEO, EMERGE commented, “Q1 2024 was a crucial setup quarter for our more focused business. We are pleased to report that GMS, the actual sales volume being transacted across our sites, is trending upwards, forming the basis for our “return to growth” plan in 2024, a top priority. Operationally, the team’s efforts in Q1 translated into year-over-year gains across gross profit, gross margin, Adjusted EBITDA, and Net Income. truLOCAL, our largest brand by revenue, saw strong net customer inflows, another key metric that drives future, deferred, revenue growth. The team is also driving visible YoY growth in our golf division, a discount-centric business, as more golf vendors seek out our marketplace services with more aggressive offers to entice customers. On the other hand, Carnivore Club, our smallest brand, is a business we have actively been optimizing for profitability, while shrinking “loss-making” revenue. Excluding Carnivore Club, our Q1 revenue was in line with Q1 2023. All in all, we are making terrific progress from topline to bottom line, notably, including positive Net Income in Q1.”

Q1 2024 Financial Highlights

Q1 GMS of $7.65M compared to $7.61M in Q1 2023Q1 Revenue of $5.0M compared to $5.3M in Q1 2023. Excluding Carnivore Club, a brand that is actively eliminating loss-making revenue, EMERGE revenue would be in line with Q1 2023Q1 Gross Profit increased to $2.1M compared to $2.0M in Q1 2023Q1 Gross Margin improved to 43% compared to 38% in Q1 2023Q1 Adjusted EBITDA improved to $(99K) compared to $(526K) in Q1 2023Net Income improved to $486K compared to Net Loss of $(2.1M), largely driven by the sale of WholesalePet (“WSP”)Net Income from Continuing Operations improved to positive $9K compared to a Net Loss of $(2.4M)Cash on hand at March 31, 2024 was $2.6 million

Cost Reductions

Following the sale of various non-core businesses over the last year, EMERGE is executing additional cost savings largely in relation to operating a more focused set of brands.

“We have taken measures to reduce our overhead expenses given our more streamlined operations that are now exclusively centered on our grocery and golf verticals. These cost reductions were partly reflected in our much improved profitability in Q1, with additional savings being actioned in Q2 as well,” continued Halazon.

Brand-Level Commentary

truLOCAL, our premium meat subscription service, and EMERGE’s largest business by revenue, continues to see strong net customer inflows, a leading indicator of future (deferred) revenue, increased Average Order Value (“AOV”), and reduced overhead expenses. The direct-to-consumer (“D2C”) subscription business is showing encouraging signs year-to-date, with ‘new initiative’ revenue lines in the works as well to accelerate organic growth.

The golf division, which includes UnderPar and JustGolfStuff, continue to drive improved topline, margins and more efficient marketing spend.

Carnivore Club, EMERGE’s smallest business, is being optimized for profitability, which includes the elimination of loss-making revenue.

Excluding Carnivore Club, EMERGE’s Q1 2024 revenue would have been approximately in line with Q1 2023.

Q1 2024 Business Highlights 

Sale of WSP

In January 2024, EMERGE completed the sale of WSP to Tiny Fund I, LP, for aggregate gross cash consideration of US$9.25M subject to certain closing adjustments and obligations.

EMERGE now retains 4 brands across 2 main verticals, Grocery and Golf, in Canada and the U.S., namely truLOCAL, Carnivore Club, UnderPar, and JustGolfStuff.

$10M Debt Paydown and Extended Term

EMERGE utilized $10M from the WSP transaction proceeds to paydown its senior credit facility with its existing lender, the principal balance of which has been reduced to $5.85M, from $15.85M prior to the completion of the transaction, and $25M originally.

On January 31, 2024, the Company entered into a second amended and restated credit agreement with its existing lender, providing a term of up to 24 months, which is comprised of an initial term of 18-months, plus an additional 6-month extension option (the “Extension”), which may be exercised upon mutual agreement between the Company and the lender. Inclusive of the Extension, the Amended Facility is expected to mature on January 31, 2026.

Notable Events Subsequent to March 31, 2024

Convertible Note Amendment Resulting in $1.39M Debt Reduction

On April 29, 2024, 100% of the holders of EMERGE’s 10% senior unsecured convertible debentures represented in person or by proxy at a meeting of debentureholders approved certain amendments to the terms of such debentures, including the creation of a redemption right and the extension of the maturity date of the debentures from November 2025 to November 2026. On the same date, EMERGE announced the redemption of $1,391,000 of principal amount of the debentures. On May 6, 2024, EMERGE completed this redemption by the issuance of 10,303,703 common shares in settlement of the principal amount and a further 360,629 common shares in settlement of the accrued and unpaid interest on the redeemed debentures, with all such shares issued at a price of $0.135 per share. The completion of the redemption effectively reduced EMERGE’s debt by $1.39 million. The amendments, the redemption and the conversion of interest are also expected to save EMERGE approximately $140K in annualized interest expense during the extended term of the debentures. The amendments also provided for an adjusted debenture conversion price of $0.135 (reduced from $0.20), which may increase the possibility of further debt reduction.

Outlook

EMERGE is seeing robust sales trends through Q2 to date, and continues to execute towards a return to organic revenue growth plan in 2024, with a substantially improved profitability profile and reduced overall debt levels.

Top Priorities

The Company’s top priorities in the near-term are to i) drive organic growth, ii) extract further operational efficiencies, and iii) opportunistically explore avenues to further pay down debt and reduce interest expense

Conference Call

Management will host a conference call on Tuesday, May 28 at 8:30 am ET to discuss its first quarter results. To access the conference call, please dial (416) 764-8650 or (888) 664-6383 and provide conference ID 66879377.

Alternatively, the conference call can be accessed online at: https://app.webinar.net/27o4Rx6jY8k 

Selected Financial Highlights

The tables below set out selected financial information and should be read in conjunction with the Company’s consolidated financial statements and MD&A for the three months ended March 31, 2024, which are available on SEDAR.

Three months ended March 31,

2024

$

2023

$

Gross Merchandise Sales1

7,645,258

7,608,218

Total revenue

5,009,051

5,325,695

Adjusted EBITDA1

(99,306)

(525,675)

Net (loss) income

485,808

(2,129,713)

Basic and diluted (loss) per share

0.00

(0.02)

1 Non-GAAP Financial Measure. Refer to section “Non-GAAP Financial Measures” for additional information.

The following table highlights Adjusted EBITDA and a reconciliation of the Company’s reported results to its adjusted measures:

Three months ended March 31,

2024

$

2023

$

Net (loss) income

485,808

(2,129,713)

Add back:

Finance costs

498,837

1,058,975

Income taxes

(170,483)

(228,060)

Amortization

59,657

794,304

EBITDA

873,819

(504,494)

Share-based compensation

25,272

77,205

Transaction cost

101,358

146,515

Foreign exchange and other losses (gains)

(623,389)

34,464

Fair value change in contingent consideration

Net loss (income) from discontinued operations

(476,366)

(279,365)

Adjusted EBITDA

(99,306)

(525,675)

The following table highlights GMS and a reconciliation of the Company’s reported results to its adjusted measures:

Three months ended March 31,

2024

$

2023

$

Revenue

5,009,051

5,325,695

Adjusted for:

Merchant costs deducted from net revenue

2,840,365

2,626,945

Sales added to deferred revenue and value of orders
fulfilled not included in revenue

1,954,445

1,593,715

Deferred and other adjustments to revenue
recognized

(1,994,282)

(1,928,954)

Advertising revenue

(164,321)

(9,183)

GMS

7,645,258

7,608,218

About EMERGE

EMERGE (TSXV: ECOM) is a premium e-commerce brand portfolio in Canada and the U.S. Our subscription and marketplace e-commerce properties provide our members with access to unique offerings across grocery and golf verticals. Our grocery businesses include truLOCAL.ca, our premium meat subscription brand, and Carnivore Club, our artisanal meat brand. Our golf businesses include UnderPar, our discounted experiences business, and JustGolfStuff, our golf products & apparel brand.

To learn more visit https://www.emerge-commerce.com/

Follow EMERGE:
LinkedIn | Twitter | Instagram | Facebook 

Cautionary notice

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Non-GAAP Measures

This press release makes reference to certain non-GAAP measures. These non-GAAP measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing a further understanding of results of operations from management’s perspective. Accordingly, they should not be considered in isolation nor as a substitute for analysis of the financial information of the Company reported under IFRS. Gross Merchandise Sales (“GMS”), EBITDA, and Adjusted EBITDA should not be construed as alternatives to revenue or net income/loss determined in accordance with IFRS. GMS, EBITDA and Adjusted EBITDA do not have any standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers.

GMS as defined by management is the total dollar value of customer purchases of goods and services, excluding applicable taxes and net of discounts and refunds. Management believes GMS provides a useful measure for the dollar volume of e-commerce transactions made through our platforms and an indicator for our business performance.

Earnings before interest, taxes, depreciation and amortization (“EBITDA”) and Adjusted EBITDA as defined by management means earnings before interest and financing costs, income taxes, depreciation and amortization, transaction costs, foreign exchange gains/losses, discontinued operations, unrealized gains/losses on contingent consideration and share-based compensation. Management believes that Adjusted EBITDA is a useful measure because it provides information about the operating and financial performance of EMERGE and its ability to generate ongoing operating cash flow to fund future working capital needs and fund future capital expenditures or acquisitions.

A reconciliation of the adjusted measures is included in the Company’s management discussion & analysis for the twelve months ended December 31, 2023 in the section “Non-GAAP Financial Measures” available through SEDAR at www.sedar.com.

Notice regarding forward-looking statements

This press release may contain certain forward-looking information and statements (“forward-looking information”) within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information.  Actual results and developments may differ materially from those contemplated by these statements.  The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, its securities, or financial or operating results (as applicable).  Although the Company believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond the Company’s control, including the risk factors discussed in the Company’s MD&A, Prospectus Supplement and Annual Information Form and are available through SEDAR at www.sedar.com. The forward-looking information contained in this press release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

On Behalf of the Board
Ghassan Halazon
Director, President and CEO

SOURCE EMERGE Commerce Ltd.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Weibo Corporation to Report First Quarter 2026 Financial Results on May 28, 2026

Published

on

By

BEIJING, April 27, 2026 /PRNewswire/ — Weibo Corporation (NASDAQ: WB and HKEX: 9898), a leading social media for people to create, share and discover content, will announce its unaudited financial results for the first quarter 2026 before the U.S. market opens on Thursday, May 28, 2026. Following the announcement, Weibo’s management team will host a conference call from 7 AM – 8 AM Eastern Time on May 28, 2026 (or 7 PM – 8 PM Beijing Time on May 28, 2026) to present an overview of the Company’s financial performance and business operations.

Participants who wish to dial in to the teleconference must register through the below public participant link. Dial in and instruction will be in the confirmation email upon registering.

Participants Registration Link: https://register-conf.media-server.com/register/BIb549b1f6935046d98b52a0fe61be918e

Additionally, a live and archived webcast of this conference call will be available at http://ir.weibo.com.

About Weibo Corporation

Weibo is a leading social media for people to create, share and discover content online. Weibo combines the means of public self-expression in real time with a powerful platform for social interaction, content aggregation and content distribution. Any user can create and post a feed and attach multi-media and long-form content. User relationships on Weibo may be asymmetric; any user can follow any other user and add comments to a feed while reposting. This simple, asymmetric and distributed nature of Weibo allows an original feed to become a live viral conversation stream.

Weibo enables its advertising and marketing customers to promote their brands, products and services to users. Weibo offers a wide range of advertising and marketing solutions to companies of all sizes. The Company generates a substantial majority of its revenues from the sale of advertising and marketing services, including the sale of social display advertisement and promoted marketing offerings. Designed with a “mobile first” philosophy, Weibo displays content in a simple information feed format and offers native advertisement that conform to the information feed on our platform. To support the mobile format, we have developed and continuously refining our social interest graph recommendation engine, which enables our customers to perform people marketing and target audiences based on user demographics, social relationships, interests and behaviors, to achieve greater relevance, engagement and marketing effectiveness

Contact:
Investor Relations
Weibo Corporation
Phone: +86 10 5898-3336
Email: ir@staff.weibo.com 

View original content:https://www.prnewswire.com/news-releases/weibo-corporation-to-report-first-quarter-2026-financial-results-on-may-28-2026-302754018.html

SOURCE Weibo Corporation

Continue Reading

Technology

Perceptive eClinical Launches Technology-Enabled Clinical Supply Consultancy in Alliance with Trialzen

Published

on

By

Expert-led clinical supply strategy powered by advanced planning and analytics technologies.

NOTTINGHAM, England and LASNE, Belgium, April 27, 2026 /PRNewswire/ — Perceptive eClinical, a leading provider of interactive response technology (IRT) and eClinical solutions, and Trialzen, an expert-led Forecasting and Supply Technology company, today announced an alliance supporting Perceptive eClinical in the launch of its Clinical Intelligence Consultancy Service, Perceptive Clinical Intelligence. This transforms its long–standing clinical supply expertise into a fully integrated, expert–led service spanning the entire clinical trial lifecycle and enabled by Trialzen’s advanced clinical supply planning technologies.

Perceptive Clinical Intelligence combines Perceptive’s deep expertise in randomization and clinical supply optimization with data-driven, technology enabled mathematical optimization, simulation, and forecasting to support smarter planning across the trial lifecycle. This integrated offering helps sponsors design, stress test, and manage clinical supply strategies with greater confidence and operational control. By formalizing its in-house expertise and therapeutic experience, Perceptive unifies randomization, trial supply management technologies and clinical supply consulting to enable more informed, scalable, and lower risk supply decision making.

“Clinical trial supply decisions are too critical to rely on tools alone,” said Malcolm Morrissey, Head of Perceptive Clinical Intelligence. “While supply discussions often focus on stock levels and overage, the real risk is patient impact. Supply availability determines whether visits happen, treatment is delivered on time, and sites can operate with confidence. Effective supply management means looking beyond IP numbers to understand patient continuity and visit level risk across the entire trial.”

Industry benchmarks show that approximately 50% of Clinical Finished Goods (CFG) manufactured for clinical trials are never administered to patients, representing hundreds of millions of dollars in wasted drug supply each year1.

“Setting up Perceptive Clinical Intelligence reflects the next step in Perceptive’s evolution, combining deep clinical supply and randomization expertise with data–driven technology to enable smarter supply planning, and increased supply confidence, and continuity across the trial lifecycle,” said Shaun Hopgood, Chief Operating Officer at Perceptive eClinical.

Perceptive eClinical and Trialzen have each delivered proven results for sponsors, with real–world engagements generating savings exceeding $1 million and materially reducing supply overage.

A Technology Enabled, Expert-Led Approach

Delivered by Perceptive’s in–house specialists, the consultancy is built on 30 years of experience supporting biotech and large pharma across randomization and clinical supply management. It combines Perceptive’s proven supply–modelling expertise with Trialzen’s advanced calculation and simulation engine, fully integrated into Perceptive’s next–generation platform, Clinphone Pro.

Anchored in deep oncology expertise, where global scale, complex dosing, and multi–layered supply chains increase planning risk, the consultancy also draws on experience across Endocrinology and Metabolism, and Infectious Diseases, and supports emerging areas such as Precision and Nuclear Medicine, and Cell and Gene Therapies. 

Reflecting on this alliance and its objectives, Cedric Druck, CEO and Co–Founder of Trialzen, commented: “Trialzen was built by clinical supply experts who spent years watching planning decisions get made on spreadsheets and gut feel, then handed off to execution systems with no feedback loop. This collaboration with Perceptive closes that gap. By integrating our forecasting and simulation capabilities directly with their IRT platform, we enable sponsors to move from scenario planning to operational action in a single environment, with full transparency at every step.”

At the heart of this alliance is a shared belief that clinical supply planning and execution should live in one connected environment. “Together, Perceptive and Trialzen are working toward a unified way of operating, where strategic decisions and day–to–day execution come together, enabling greater visibility, smarter scenarios, and more confident supply decisions from manufacturing through to patient dosing”. said Tony Street, Senior Vice President Strategy at Trialzen.

Clients benefit from:

Faster study start-up and smoother amendments through early supply optimizationHigher quality supply decisions driven by expert oversight and data backed insightGreater confidence through strategic expert consultancy for complex trialsMid-study forecast adjustments and up-to-date quantitative support for key decisions

About Perceptive eClinical

Perceptive eClinical is a trusted leader in delivering advanced trial capabilities. With over 30 years of proven Interactive Response Technology (IRT) and supply management expertise, more than 500 regulatory approvals and support for three million patients worldwide, we deliver reliability, security and precision. This is reflected in our consistently high customer satisfaction score of 4.5 out of 5 over the past three years. Our future-proof IRT solution, Clinphone Pro, helps sponsors manage the speed, complexity and personalization of modern clinical trials. Built for flexibility and seamless integration, it supports smarter, more efficient studies across all phases and therapeutic areas. In 2025, Perceptive eClinical was recognized as a leader in Everest Group’s PEAK Matrix® Assessment for RTSM Solutions, affirming our commitment to innovation, global delivery excellence and measurable value for sponsors and CROs.

About Trialzen

Trialzen is a technology company built by industry experts specializing in clinical trial supply forecasting and planning. Its Forecast & Planning Solution (FPS) is a purpose-built SaaS platform that enables sponsors and CROs to model, simulate, and optimize clinical supply strategies across the full trial lifecycle. Built by clinical supply experts, Trialzen combines advanced mathematical modelling and analytics with a transparent, user-friendly interface, allowing teams to evaluate scenarios, anticipate risk, and make informed supply decisions with speed and confidence. 

Sources

McKinsey & Company, Clinical Supply Chains insights

Media Contact: Zara Broadfield, Marketing Director Perceptive eClinical, zara.broadfield@perceptive.com 

Logo – https://mma.prnewswire.com/media/2965426/Perceptive_eClinical.jpg
Logo – https://mma.prnewswire.com/media/2965427/5936695/Trialzen.jpg

 

 

View original content:https://www.prnewswire.co.uk/news-releases/perceptive-eclinical-launches-technologyenabled-clinical-supply-consultancy-in-alliance-with-trialzen-302754074.html

Continue Reading

Technology

Mouser Electronics New Product Insider: Over 9,000 New Parts Added in First Quarter of 2026

Published

on

By

SHANGHAI, April 27, 2026 /PRNewswire/ — As an authorized distributor, Mouser Electronics, Inc. is focused on the rapid introduction of new products and technologies, giving customers an edge and helping speed time to market. Over 1,200 semiconductor and electronic component manufacturer brands count on Mouser to help them introduce their products into the global marketplace. Mouser’s customers can expect 100% certified, genuine products that are fully traceable from each manufacturer.

Last quarter, Mouser launched more than 9,000 part numbers ready for shipment. Some of the products introduced by Mouser from January through March 2026 include:

STMicroelectronics STM32C5 Arm® Cortex®-M33 Microcontrollers
The STM32C5 microcontrollers (MCUs) from STMicroelectronics are specifically designed to boost the performance of billions of tiny smart devices across factories, homes, cities, and infrastructure while meeting stringent cost, size, and power constraints. Based on ST’s proprietary 40 nm manufacturing process, the STM32C5 MCUs can run tasks noticeably faster than many entry-level chips currently in use. This gives products more room to include features such as improved sensing, smoother control, and enhanced user experiences while keeping dynamic power consumption low. The MCUs also integrate security features that help safeguard products against tampering and cyber risks.EDATEC ED-CM0NANO Single-Board Computer
The ED-CM0NANO is a single-board computer (SBC) from EDATEC, based on the Raspberry Pi Compute Module Zero (CM0). The ED-CM0NANO features a quad-core Arm Cortex-A53 processor running at up to 1 GHz, a Broadcom VideoCore-IV graphics processor, and a wide range of connectivity options. Optional Wi-Fi® support with an external antenna enables wireless connectivity, while integrated real-time clock (RTC) and watchdog timer enhance system reliability. These features make the ED-CM0NANO ideal for industrial control systems and Internet of Things (IoT) applications.Sensata Technologies MGD Resonix™ Refrigerant Leak Sensor
The MGD Resonix™ sensor from Sensata delivers high accuracy and fast response times in a compact module that fits into the smallest heating, ventilation, air conditioning (HVAC), and refrigeration equipment. The MGD series offers superior resistance to overexposure and poisoning, as well as to high temperatures (working temperatures up to 105 °C) and humidity. These devices also have a service life of more than 15 years with no need for calibration, making them the ideal leak-detection component for A2L HVAC and refrigeration systems.u-blox ANN-MB3 Triple-Band GNSS Antenna
The ANN-MB3 from u-blox is a best-in-class L1/L2/L5 triple-band RTK real-time kinematic (RTK) solution ideal for the F20 high-precision GNSS. Optimized for seamless integration, the ANN-MB3 antenna delivers exceptional performance with a robust design. The antenna’s compact (62 × 80 × 25.5 mm) form factor and flexible installation options enable the adoption of high-precision positioning technologies across industrial, automotive, and robotics applications.

To see more of the New Product Insider highlights, go to https://info.mouser.com/new_products/.

For more Mouser news and our latest new product introductions, visit https://www.mouser.com/newsroom/.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/mouser-electronics-new-product-insider-over-9-000-new-parts-added-in-first-quarter-of-2026–302754079.html

SOURCE Mouser Electronics

Continue Reading

Trending